At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Sebastien Beauzile, 21, is the first New Yorker to have received the breakthrough Lyfgenia treatment, according to the New ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

CRISPR technology has revolutionised genetic engineering, offering unprecedented precision in DNA editing with vast implications for medicine, agriculture and conservation. Yet, its power demands ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...